Medical devices, healthcare technology and the business of care
PMA approval · P200039

Shockwave Intravascular Lithotripsy (IVL) System with Shockwave C2 Coronary Intravascular Lithotripsy (IVL) Catheter

Shockwave Medical, Inc. · Decision date Feb 12, 2021

MEDTECHLEDGER EXPLANATIONP200039

What did the FDA approve?

The FDA database entry records an approval decision dated February 12, 2021, for the Shockwave Intravascular Lithotripsy (IVL) System with Shockwave C2 Coronary Intravascular Lithotripsy (IVL) Catheter. The stated indication is lithotripsy-enabled, low-pressure balloon dilatation of severely calcified, stenotic de novo coronary arteries prior to stenting.

The entry lists Shockwave Medical, Inc. as the applicant, with product code QMG under the cardiovascular specialty. No supplement type or supplement reason is provided, so the record does not identify this as a change to a prior PMA. The source statement describes the reported intended use; it does not independently establish safety or clinical effectiveness.

FDA approval order statement

Approval for the Shockwave Intravascular Lithotripsy (IVL) System with Shockwave C2 Coronary Intravascular Lithotripsy (IVL) Catheter. The Shockwave Intravascular Lithotripsy (IVL) System with Shockwave C2 IVL Coronary Catheter is indicated for lithotripsy-enabled, low-pressure balloon dilatation of severely calcified, stenotic de novo coronary arteries prior to stenting.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Feb 12, 2021

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P200039
Regulatory pathway
Premarket approval application
Product code
QMG
Decision code
APPR
Decision date
Feb 12, 2021
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Shockwave intravascular lithotripsy system.

Product code
QMG
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P200039 received

    Application receipt date recorded by FDA.

  2. P200039 · FDA decision

    APPR

  3. P200039/S025 · Related supplement

    SHOCKWAVE INTRAVASCULAR LITHOTRIPSY (IVL) SYSTEM WITH SHOCKWAVE C2/C2+ CORONARY IVL CATHETER

Timeline entries are records held by MedtechLedger for P200039. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200039

Product / regulatory recordCompanyPathwayDecision dateSource
Shockwave Medical, Inc.PMA supplementSep 11, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Shockwave Medical, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
5403 Betsy Ross Dr., Santa Clara, CA, 95054

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records